13.07.2015 Views

The world according to Monsanto : pollution, corruption, and

The world according to Monsanto : pollution, corruption, and

The world according to Monsanto : pollution, corruption, and

SHOW MORE
SHOW LESS
  • No tags were found...

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

200 the <strong>world</strong> <strong>according</strong> <strong>to</strong> monsan<strong>to</strong>technologies,” <strong>and</strong> continued: “As we work <strong>to</strong> help develop constructive answers<strong>to</strong> all the questions that people around the <strong>world</strong> have at the dawningof this new technology, we are committed <strong>to</strong> engage openly, honestly <strong>and</strong>non-defensively in the kind of discussion that can produce good answers forall of us. ...To me, that means, among other things, listening carefully <strong>and</strong>respectfully <strong>to</strong> all points of view.”As he spoke those words, Shapiro was desperately seeking a partner <strong>to</strong>save the company. First, he held discussions with American Home Products,then with DuPont, but the deals fell through. Finally, on December 19,1999, Monsan<strong>to</strong> announced its merger with Pharmacia <strong>and</strong> Upjohn, originallya Swedish pharmaceutical company based in New Jersey. “<strong>The</strong> termsof the merger signaled the failure of Monsan<strong>to</strong>’s guiding vision <strong>and</strong> of its crea<strong>to</strong>r,Robert Shapiro,” <strong>according</strong> <strong>to</strong> Michael Watkins, a researcher at HarvardBusiness School. 47 Renamed Pharmacia, the new corporation was interestedprimarily in Searle, Monsan<strong>to</strong>’s pharmaceutical division, whose value wasthen estimated at $23 billion (it manufactured Celebrex, a leading medicinefor arthritis). But it soon sought <strong>to</strong> separate from the agrichemical divisionof Monsan<strong>to</strong>, known as “the new Monsan<strong>to</strong>,” which it finally did in the summerof 2002 (at the same time that Pharmacia was absorbed by Pfizer).<strong>The</strong> messianic vision of Robert Shapiro, who had dreamed of a companydedicated <strong>to</strong> the life sciences, was well <strong>and</strong> truly buried. When he left thecompany after the merger with Pharmacia in late 1999, the firm displayedits true face: it was indeed the largest supplier in the <strong>world</strong> of transgenicseeds, but it got 45 percent of its revenues from Roundup, which was threatenedby the arrival of generics. Shapiro was replaced by the Belgian HendrikVerfaillie, who was in turn forced <strong>to</strong> resign in December 2002 because of“poor financial performance.” 48 He was succeeded by the Scotsman HughGrant (still CEO in early 2008), who had the delicate task of getting thingsback on an even keel, while GMOs enjoyed anything but universal supportin North America, not even in farmers’ fields.

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!